Octreotide, sold as Sandostatin, is one of medicine's most effective off switches. It is a lab-made copy of somatostatin, the hormone the body uses to quiet the pancreas, and it can shut the islet's hormone output down by more than 90 percent. A drip of amino acids pushed a large share of that output back up.
The work, published June 12 in The Journal of Physiology ↗, ran an unusually direct test in 15 healthy volunteers. Each person got an intravenous infusion of amino acids (a clinical preparation called Vamin), the building blocks of protein, on its own, then again while octreotide ↗ ran for four hours to clamp the pancreas down, and octreotide on its own for comparison. Throughout, the team tracked three hormones in the blood: glucagon ↗, which raises blood sugar; insulin, which lowers it; and C-peptide ↗, a fragment released alongside insulin that gives a clean readout of how much insulin the pancreas is actually making.
Octreotide alone did what it is known to do. Glucagon and insulin fell by more than 90 percent, and C-peptide by more than 65 percent. The pancreas went quiet.
Amino acids alone did the opposite, lifting all three hormones. The real question was what happens when both signals arrive at once. Does the brake hold, or does the nutrient signal break through? It broke through. With amino acids flowing on top of octreotide, glucagon climbed back to 49 percent of its amino-acid-only level, insulin to just under half, and C-peptide to 78 percent. The brake was still pressed hard, and the hormones came up anyway.
That partial escape is the point. Somatostatin, and the drugs built on it, work by raising the bar a cell has to clear before it secretes. A strong enough stimulus can still clear it. Amino acids, it turns out, are a strong enough stimulus, and the breakthrough was not limited to the glucagon-making alpha cells. The insulin-making beta cells did it too.
This is more than a curiosity about an old drug. Too much glucagon in the blood, called hyperglucagonemia, is a feature of type 2 diabetes and of fatty liver disease, now formally named metabolic dysfunction-associated steatotic liver disease, or MASLD, and it persists even though the body's own somatostatin should be reining it in. The study offers a mechanism for that stubbornness. In people with high circulating amino acids, common in both conditions, the nutrient signal may simply keep overpowering the brake. The authors frame it as a balance of signals, where amino acids can counteract somatostatin without fully overcoming it.
It also draws a line around what somatostatin-based drugs can do. Octreotide and its longer-acting relatives, lanreotide (Somatuline) and pasireotide (Signifor), are mainstays for acromegaly and for hormone-secreting tumors such as carcinoid syndrome and neuroendocrine tumors, conditions where the goal is to clamp an overactive gland. The finding says the clamp is conditional. Feed the system a strong enough competing signal and a measurable fraction of secretion returns, even near the drug's ceiling. The body's strongest hormonal brake has a nutrient-sized gap in it.
For peptidemodel, the piece sits where several hosted cards meet. Octreotide acts on the somatostatin receptor SSTR2 ↗; the hormones it failed to fully suppress, glucagon and the insulin tracked through C-peptide, act through the glucagon receptor GCGR ↗ and the insulin receptor ↗. The experiment is a reminder that a receptor agonist's real effect depends on what else is competing for the cell's attention.